Gebo Biotech
格博生物
Gebo Biotech (格博生物) is a clinical-stage biotechnology company focused on developing innovative molecular glue degraders, and a Qiming Venture Partners portfolio company . Two recent milestones stand out in the coverage: in February 2026 it received a $30 million strategic equity investment from Sanofi , and by May 2026 China's NMPA had approved its Phase II trial application for GLB-002 — a next-generation IKZF1/IKZF3 selective molecular glue degrader — in combination with rituximab . It was also named to the 2025 China Future Unicorn Top 100 list alongside other Qiming portfolio companies . Beyond these points, elsewhere's corpus carries no deeper profile of the company's founding or full pipeline.
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Vol.16, May 12, 2026
Staying with you through milestone moments at Qiming Venture Partners' portfolio companies
Qiming Weekly: Top 10 Portfolio Company Updates, Vol. 06, Feb. 25, 2026
Staying with you through milestone moments for Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Morning Star | Over 20 Qiming Venture Partners Portfolio Companies Named to 2025 China Future Unicorn Top 100 and Other Lists
The selection process isn't just a deep dive into innovative companies — it also gives investors a chance to spot potential winners.
